MBX Biosciences, Inc.

MBX Biosciences reported a net loss of $37.1 million for Q2 2026, significantly higher than $19.4 million in Q2 2025, primarily due to increased research and development and general and administrative expenses. The company successfully raised $85.0 million net from an at-the-market offering in February 2026 and subsequently increased its ATM capacity to $250.0 million. MBX maintains $418.6 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least the next 12 months.

MBX Biosciences reported a net loss of $37.1 million for the second quarter of 2026, an increase from $19.4 million in the same period last year, driven by higher R&D and G&A expenses. Despite the increased loss, the company maintains a strong cash position of $418.6 million, projected to fund operations into 2029. Key corporate highlights include the recruitment for the Phase 3 trial of canvuparatide, positive initial Phase 1 data for MBX 4291 in obesity, and the nomination of new obesity drug candidates MBX 6180 and MBX 5765, alongside executive leadership changes.

MBX Biosciences, Inc. announced a leadership transition, with Kent P. Hawryluk stepping down as Chief Executive Officer and Board member effective July 13, 2026. He will assist with the transition and provide strategic advisory services until August 16, 2026. Concurrently, Steven Hoerter, the company's current Executive Chairman, has been appointed as the new President and Chief Executive Officer, also effective July 13, 2026. Mr. Hoerter's compensation package includes a base salary of $665,000, a target annual bonus of 60%, and significant equity awards.

MBX Biosciences announced significant leadership changes, appointing Steve Hoerter as its new Chairman and Chief Executive Officer, succeeding co-founder Kent Hawryluk. John Smither, previously Interim CFO, has been named Chief Financial Officer. These changes are effective immediately. The company also reaffirmed its commitment to key milestones in the second half of 2026, including initiating a Phase 3 trial for canvuparatide and releasing data for MBX 4291.

MBX Biosciences announced positive one-year data from its Phase 2 clinical trials for canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism. The data demonstrate sustained benefits, including maintenance of calcium homeostasis, improved kidney function, and normalized bone turnover markers. The drug was well-tolerated, and the company remains on track to initiate its Phase 3 pivotal trial in Q3 2026.

MBX Biosciences announced positive full results from its 12-week Avail™ Phase 2 trial and new one-year data from the open-label extension (OLE) study of once-weekly canvuparatide for chronic hypoparathyroidism. The OLE showed a 57% responder rate at one year, comparable to the 63% at 12 weeks in Phase 2, with 90% patient retention. The drug was well tolerated, demonstrated consistent PTH activity, improved kidney function, and normalized bone metabolism. The company remains on track to initiate its Phase 3 pivotal trial in Q3 2026.

MBX Biosciences, Inc. held its 2026 annual meeting of stockholders on June 4, 2026. During the meeting, stockholders approved the election of Patrick J. Heron and Edward T. Mathers as Class II directors, each to serve a three-year term until the 2029 annual meeting. Additionally, stockholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

MBX Biosciences, a clinical-stage biopharmaceutical company, announced that its President and CEO, Kent Hawryluk, and Chief Medical Officer, Sam Azoulay, M.D., will present at the Jefferies 2026 Global Healthcare Conference on June 3, 2026. The presentation will take place from 8:10 a.m. to 8:40 a.m. ET and will be accessible via a live webcast on the company's investor relations website, with a replay available for approximately 90 days. The company will provide updates on its pipeline, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development, and its obesity portfolio candidates, MBX 4291 in Phase 1 and MBX 5765 in preclinical development.

MBX Biosciences provided an update on its obesity portfolio, including initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug. The preliminary blinded data showed a mean weight loss of 7% at 8 weeks and a pharmacokinetic profile supportive of once-monthly dosing with good tolerability. The company also nominated MBX 5765 as its lead amycretin prodrug candidate and announced proof of concept for imapextide in post-bariatric hypoglycemia, though further investment in imapextide's Phase 2b will be deprioritized to focus on other programs.

MBX Biosciences announced positive preliminary blinded data from its ongoing Phase 1 trial for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, demonstrating a mean weight loss of 7% at 8 weeks and good tolerability. The company also nominated MBX 5765 as its lead amycretin prodrug candidate, a novel GLP-1/GIP/glucagon/DACRA agonist designed for once-monthly dosing, with IND-enabling studies expected in Q2 2026. Additionally, imapextide achieved positive proof of concept in its Phase 2a STEADI™ trial for post-bariatric hypoglycemia, though the company will not pursue further Phase 2b investment, opting to prioritize its expanding obesity pipeline.